-
Moffitt Cancer Center in Tampa helped study the imaging drug, which the FDA recently approved. It draws attention to hard-to-spot tumors during surgery.
-
A new Alzheimer's drug isn't reaching many patients. Doctors say reasons include its high cost, and lingering questions about its effectiveness.
-
The New York attorney general says Johnson & Johnson has agreed to pay $230 million to settle claims that the pharmaceutical giant helped fuel the opioid crisis.
-
At issue is a provision that requires physicians to have in-person consultations with patients before prescribing obesity-treatment drugs, which is inconsistent with the state’s telehealth law.
-
The agency is to decide by Monday whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November.
-
It's been two weeks since the president signed an executive order to put "America First" on drug prices. But pharmaceutical companies aren't ready to negotiate.
-
The president says the actions will lower drug prices, but policy experts say they will likely offer patients only minimal relief and may take months to implement, if they're implemented at all.
-
It can be hard enough finding a doctor who prescribes buprenorphine, a medication used to treat opioid addiction. But patients also report difficulty with pharmacies that refuse to stock the drug.
-
It was expected to be a perfunctory statehouse meeting — three lobbyists and a legislator discussing a proposal to educate Louisiana doctors about the…
-
Some cities, counties and school districts in Florida and around the country are helping their employees buy cheap prescription drugs from Canada and…